Cargando…

Erlotinib Induced Fatal Interstitial Lung Disease in a Patient with Metastatic Non-Small Cell Lung Cancer: Case Report and Review of Literature

Erlotinib is one of the most widely used tyrosine kinase inhibitor targeting human epidermal growth factor receptor. Since its introduction, it has revolutionized the treatment of advanced non-small cell lung cancer. Skin rashes and diarrhea are the most often reported side effects of erlotinib howe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mangla, Ankit, Agarwal, Nikki, Carmel, Chou, Lad, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	PAGEPress Publications, Pavia, Italy 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064300/ https://www.ncbi.nlm.nih.gov/pubmed/27746884 http://dx.doi.org/10.4081/rt.2016.6410

Ejemplares similares

Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer
por: Makris, Demosthenes, et al.
Publicado: (2007)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

Fatal Interstitial Lung Disease after Addition of Sorafenib to a Patient with Lung Adenocarcinoma Who Had Failed to Improve with Erlotinib Alone
por: Guan, Yin, et al.
Publicado: (2014)

Erlotinib Achieved Partial Response in a Non-Small Cell Lung Cancer Patient with Gefitinib-Induced Interstitial Lung Disease
por: Tian, Qing, et al.
Publicado: (2011)

Interstitial lung disease associated to erlotinib treatment: a case report
por: del Castillo, Yolanda, et al.
Publicado: (2010)

Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib
por: Melosky, B., et al.
Publicado: (2008)

RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
por: Nakagawa, Kazuhiko, et al.
Publicado: (2022)

Review of erlotinib in the treatment of advanced non-small cell lung cancer
por: Ganjoo, Kristen N, et al.
Publicado: (2007)

The effect of sarcopenia on erlotinib therapy in patients with metastatic lung adenocarcinoma
por: Topcu, Atakan, et al.
Publicado: (2022)

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET
por: Abourbeh, Galith, et al.
Publicado: (2015)

EGFR testing and erlotinib use in non-small cell lung cancer patients in Kentucky
por: Larson, Kara L., et al.
Publicado: (2020)

Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib
por: Aydiner, Adnan, et al.
Publicado: (2015)

Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer
por: Li, Fei, et al.
Publicado: (2017)

Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY
por: Nishio, Makoto, et al.
Publicado: (2020)

A comparative study on erlotinib & gefitinib therapy in non-small cell lung carcinoma patients
por: Thomas, Preenumol, et al.
Publicado: (2019)

Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review
por: Agarwal, Nikki, et al.
Publicado: (2021)

Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
por: Emery, Ivette F, et al.
Publicado: (2009)

Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer
por: KABURAGI, TAKAYUKI, et al.
Publicado: (2013)

Docetaxel-carboplatin in combination with erlotinib and/or bevacizumab in patients with non-small cell lung cancer
por: Boutsikou, Eftimia, et al.
Publicado: (2013)

Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
por: Li, Wei, et al.
Publicado: (2014)

Adherence, exposure and patients’ experiences with the use of erlotinib in non-small cell lung cancer
por: Timmers, Lonneke, et al.
Publicado: (2015)

YAP promotes erlotinib resistance in human non-small cell lung cancer cells
por: Hsu, Ping-Chih, et al.
Publicado: (2016)

Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer
por: Pal, A.S., et al.
Publicado: (2020)

Atypical response to erlotinib in a patient with metastatic lung adenocarcinoma: a case report
por: Sakhri, Linda, et al.
Publicado: (2014)

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results
por: Garon, E.B., et al.
Publicado: (2023)

Telomeres in Interstitial Lung Disease
por: Stock, Carmel J. W., et al.
Publicado: (2021)

RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability
por: Nadal, Ernest, et al.
Publicado: (2021)

Acute Fatal Liver Toxicity under Erlotinib
por: Schacher-Kaufmann, Sabina, et al.
Publicado: (2010)

Bowel Perforation after Erlotinib Treatment in a Patient with Non-Small Cell Lung Cancer
por: Cheon, Yun-Hong, et al.
Publicado: (2011)

Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer
por: Reguart, Noemí, et al.
Publicado: (2010)

EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer
por: Baty, Florent, et al.
Publicado: (2013)

Repurposing sertraline sensitizes non–small cell lung cancer cells to erlotinib by inducing autophagy
por: Jiang, Xingwu, et al.
Publicado: (2018)

Minocycline-Induced Hyperpigmentation in a Patient Treated with Erlotinib for Non-Small Cell Lung Adenocarcinoma
por: Bell, Ann T., et al.
Publicado: (2017)

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer
por: Rudin, C.M., et al.
Publicado: (2023)

Engineering of Amphiphilic Erlotinib Analogue as Novel Nanomedicine for Non-Small Cell Lung Cancer Therapy
por: Cong, Mei, et al.
Publicado: (2023)

Metastasis of cervical cancer to breast: A case report and review of literature
por: Mangla, Ankit, et al.
Publicado: (2017)

Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States
por: Enewold, Lindsey, et al.
Publicado: (2016)

Maintained Complete Response and Long-Term Survival in Epidermal Growth Factor Receptor Mutated Metastatic Non-Small Cell Lung Cancer with Erlotinib
por: Alkassis, Samer, et al.
Publicado: (2021)

Long Term Survivor with Erlotinib in Metastatic Lung Cancer-Squamous Cell Carcinoma Subtype
por: VATU, BOGDAN IONEL, et al.
Publicado: (2020)

Non-small Cell Lung Cancer with Multiple Brain Metastases Treated with Radiosurgery and Erlotinib: A Case Report
por: Sahin, Bilgehan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8jgc81a9078gdbbv6i0ki146ml